Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options

医学 肾细胞癌 肿瘤科 内科学 生物 癌症研究 病理
作者
Nathaniel R. Wilson,Yusuf Açıkgöz,Elshad Hasanov
出处
期刊:International Journal of Cancer [Wiley]
卷期号:154 (6): 947-961 被引量:16
标识
DOI:10.1002/ijc.34756
摘要

Abstract Non‐clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts younger patients, and is often metastatic at presentation. Compared to clear‐cell RCC (ccRCC), nccRCC typically has a worse prognosis in the metastatic setting, with overall survival durations that are ~10 months shorter. The nccRCC consists of a wide range of different histological subtypes, the majority of which are composed of papillary, chromophobe, renal medullary carcinoma, translocation RCC, collecting duct carcinoma and unclassified RCC. Most clinical trials have either excluded or only included small numbers of patients with nccRCC; owing to the lack of prospective studies focusing on this population, data on response rates and survival outcomes are lacking. NccRCC treatment is a nascent field with various therapeutic modalities and combinations under investigation, often based on data extrapolated from therapeutic studies in ccRCC. We herein review the use and outcomes of cytotoxic chemotherapy, various combination modalities of tyrosine kinase inhibitors and immune checkpoint inhibitors, and targeted agents. We discuss active ongoing clinical trials for patients with nccRCC and future directions in the treatment of this rare disease. Historically, treatment for nccRCC has been adopted from the standard of care for patients with ccRCC, although these treatments are less effective in the nccRCC population. As we begin to understand the underlying biology of these tumors, clinical trials have been able to slowly accrue and include more patients with various subtypes of nccRCC. There remains much room for improvement in this area of need, but there is hope on the horizon.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
yaoyaoy完成签到,获得积分10
2秒前
夕禾完成签到,获得积分10
2秒前
布丁奶绿lv完成签到,获得积分10
2秒前
green发布了新的文献求助10
3秒前
3秒前
和谐秋荷完成签到,获得积分10
3秒前
4秒前
小安发布了新的文献求助10
4秒前
范范范完成签到 ,获得积分10
4秒前
焦哈哈发布了新的文献求助10
4秒前
4秒前
深情安青的应助被乐观冥幽采纳,获得10
4秒前
4秒前
5秒前
5秒前
5秒前
5秒前
5秒前
窦天蓝完成签到,获得积分10
5秒前
5秒前
完美世界的应助被XH采纳,获得10
5秒前
5秒前
5秒前
5秒前
6秒前
6秒前
6秒前
lan2720完成签到 ,获得积分10
6秒前
7秒前
7秒前
白色噪音完成签到,获得积分20
8秒前
9秒前
9秒前
Tuniverse_发布了新的文献求助10
10秒前
10秒前
chengsi完成签到,获得积分10
10秒前
10秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621